About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
Is Amazon a Good E-Commerce Stock to Buy in 2022?
E-commerce giant (AMZN) has been one of the pandemic’s biggest winners because demand for online shopping skyrocketed over the past 20 months. However, its stock is the worst-performing among the FAANG group. So, will AMZN’s stock generate better momentum this year? Read more to find out.
Is Apple a Good FAANG Stock to Own in 2022?
Tech giant Apple (AAPL) made history this week by becoming the first company in the world to hit a $3 trillion market cap. The company’s latest technological inventions and product updates position it well to dominate the tech industry over the long term. However, with its massive investments in autonomous driving technology, will AAPL successfully penetrate the EV space? Read more to learn our view.
Up More Than 200% in December, is Insignia Systems Still a Buy?
Ad-tech company Insignia Systems (ISIG) rallied more than 200% in December 2021, markings its best market performance since its IPO in 1991. With increasing meme trader attention, will ISIG be able to continue to rally? Read more to find out.
Is 22nd Century Group a Buy After the FDA Grants Approval to Market its VLN Cigarettes
Biotech company 22nd Century Group (XXII) received FDA approval to market its VLN Group cigarettes as modified risk tobacco products on December 23, 2021.The cigarettes contain 95% less nicotine than traditional cigarettes. But should one invest in XXII now with its negative profit margins and ROE? Read more to learn our view.
Down Over 30% in 2021, is MaxCyte Still a Buy?
Cell-based therapies developer MaxCyte (MXCT) made a stellar stock market debut in July last year. However, the stock has lost more than 30% since then, closing yesterday’s trading session at $10.84. With poor financials and profit margins, will MXCT recover this year? Read more to find out.
After Skyrocketing 2021, Does Ford Motor Stock Have More Room to Run?
The shares of legacy automaker Ford Motor (F) have surged in price in triple digit percentage terms over the past year because investors have been betting on it to become a game-changer in the electric vehicle (EV) space. So, with an impressive product line-up, will F be able to maintain its momentum this year? Read more to learn our view.
Will Shares of Sundial Growers Rebound in 2022?
Canadian cannabis company Sundial Growers (SNDL) has been slumping over the past six months, as investors have lost interest in the penny stock. As SNDL focuses on acquiring the largest liquor retailer in Canada, will the stock regain its momentum this year
Is American Virtual Cloud Technologies a Worthwhile Meme Stock to Own?
Global IT solutions provider American Virtual Cloud Technologies (AVCT) is currently one of the most discussed stocks in the popular Reddit forum r/shortsqueeze. Up more than 70% over the past month, will AVCT’s momentum continue in the near term?
Is Morgan Stanley a Good Financial Company to Buy for 2022?
Leading financial services firm Morgan Stanley (MS) has outperformed the broader S&P 500 index last year. With double-digit revenue and earnings growth in the trailing 12 months, MS largely benefited from the increasing demand for loans and trading activities over this period. However, amid concerns surrounding a potential market correction and the Fed’s hawkish tilt, is MS an ideal investment now? Read more to find out.